Effects of vasoactive intestinal polypeptide (VIP) on lower esophageal sphincter in awake baboons: comparison with glucagon and secretin. 1979

S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said

The effects of vasoactive intestinal polypeptide (VIP), glucagon, and secretin on lower esophageal sphincter pressure were investigated in awake baboons. The three hormones were compared with respect to effect on (1) resting lower esophageal sphincter pressure and (2) maximal stimulatory response to pentagastrin. VIP was shown to reduce resting and pentagastrin-stimulated lower esophageal sphincter pressure with significantly greater potency than either secretin or glucagon. For reduction of resting lower esophageal sphincter pressure, the potency ratio of VIP to secretin was 16:1 and of VIP to glucagon was 32:1 (P less than 0.05). For inhibition of pentagastrin-stimulated sphincter pressure, the potency ratio of VIP to secretin was 32:1 and of VIP to glucagon was 64:1 (P less than 0.02). This demonstration of significantly increased potency of VIP over known inhibitory hormones strengthens the suggestion that VIP may have a physiologic role in the control of lower esophageal sphincter function.

UI MeSH Term Description Entries
D008297 Male Males
D010215 Papio A genus of the subfamily CERCOPITHECINAE, family CERCOPITHECIDAE, consisting of five named species: PAPIO URSINUS (chacma baboon), PAPIO CYNOCEPHALUS (yellow baboon), PAPIO PAPIO (western baboon), PAPIO ANUBIS (or olive baboon), and PAPIO HAMADRYAS (hamadryas baboon). Members of the Papio genus inhabit open woodland, savannahs, grassland, and rocky hill country. Some authors consider MANDRILLUS a subgenus of Papio. Baboons,Baboons, Savanna,Savanna Baboons,Baboon,Baboon, Savanna,Papios,Savanna Baboon
D010418 Pentagastrin A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. Acignost,Gastrin Pentapeptide,Peptavlon,Pentapeptide, Gastrin
D011312 Pressure A type of stress exerted uniformly in all directions. Its measure is the force exerted per unit area. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Pressures
D012146 Rest Freedom from activity. Rests
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004943 Esophagogastric Junction The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice. Gastroesophageal Junction,Gastroesophageal Junctions,Junction, Esophagogastric,Junction, Gastroesophageal,Junctions, Gastroesophageal
D005768 Gastrointestinal Hormones HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs. Enteric Hormone,Enteric Hormones,Gastrointestinal Hormone,Intestinal Hormone,Intestinal Hormones,Hormone, Enteric,Hormone, Gastrointestinal,Hormone, Intestinal,Hormones, Enteric,Hormones, Gastrointestinal,Hormones, Intestinal
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor

Related Publications

S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
November 1979, Gastroenterology,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
April 1984, The Journal of clinical investigation,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
January 1981, Diabetologia,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
August 1992, Gastroenterology,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
November 1993, Gastroenterology,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
July 1975, Israel journal of medical sciences,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
June 2002, Nihon rinsho. Japanese journal of clinical medicine,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
S R Siegel, and F C Brown, and D O Castell, and L F Johnson, and S I Said
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!